It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The National Institute of Health (NIH) Library of integrated network-based cellular signatures (LINCS) program is premised on the generation of a publicly available data resource of cell-based biochemical responses or “signatures” to genetic or environmental perturbations. NeuroLINCS uses human inducible pluripotent stem cells (hiPSCs), derived from patients and healthy controls, and differentiated into motor neuron cell cultures. This multi-laboratory effort strives to establish i) robust multi-omic workflows for hiPSC and differentiated neuronal cultures, ii) public annotated data sets and iii) relevant and targetable biological pathways of spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). Here, we focus on the proteomics and the quality of the developed workflow of hiPSC lines from 6 individuals, though epigenomics and transcriptomics data are also publicly available. Known and commonly used markers representing 73 proteins were reproducibly quantified with consistent expression levels across all hiPSC lines. Data quality assessments, data levels and metadata of all 6 genetically diverse human iPSCs analysed by DIA-MS are parsable and available as a high-quality resource to the public.
Measurement(s) | Protein expression |
Technology Type(s) | Mass Spectrometry |
Factor Type(s) | genetically distinct human cell lines |
Sample Characteristic - Organism | Homo sapiens |
Sample Characteristic - Location | United States |
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Cedars-Sinai Medical Center, NeuroLINCS, Advanced Clinical Biosystems Research Institute, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
2 Cedars-Sinai Medical Center, NeuroLINCS, Regenerative Medicine Institute, Los Angeles, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
3 NeuroLINCS, Department of Biological Engineering, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
4 University of California San Francisco, NeuroLINCS, Gladstone Institute of Neurological Disease and the Departments of Neurology and Physiology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 Johns Hopkins University, NeuroLINCS, Department of Neuroscience, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
6 University of California Irvine, NeuroLINCS, Departments of Psychiatry and Human Behaviour, Neurobiology and Behaviour and UCI MIND, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)